FDA issues warning letter to Intas’ plant in north India; okays Axsome’s drug for Alzheimer’s-related agitation
In Phispers this week, India’s Intas Pharmaceuticals received a warning letter from the US Food and Drug Administration (...
Impressions : 2065
FDA seeks more safety data from Lilly on obesity drug Foundayo; Novo partners OpenAI to speed up drug development
This week’s Phispers brings you news on how artificial intelligence (AI) is taking centerstage in the world of pharmaceut...
Impressions : 2328
Neurocrine buys Soleno for US$ 2.9 bn; Novo says Wegovy pill outperforms Lilly’s Foundayo in cross-trial comparison
In Phispers this week, Neurocrine Biosciences announced the
acquisition of rare-disease drugmaker Soleno Therapeutics for US$ ...
Impressions : 1511
Lilly in US$ 7.8 bn deal to acquire Centessa for its sleep disorder pipeline; bags FDA nod for obesity med orforglipron
In Phispers this week, the US Food and Drug Administration (FDA) approved Eli Lilly’s Foundayo (orforglipron), a once-dai...
Impressions : 1358
Lilly to invest US$ 3 bn in China to boost supply of new obesity drug; Servier acquires Day One Biopharma for US$ 2.5 bn
In Phispers this week, Eli Lilly announced its plans to invest US$
3 billion in China over the next decade in order to build p...
Impressions : 2555
FDA agrees to review Moderna’s amended mRNA-based flu vaccine application; Lilly builds orforglipron stock ahead of approval
Last week, the US Food and Drug Administration (FDA) had said it will not review Moderna’s application for its experiment...
Impressions : 1873
J&J’s 2026 sales may cross US$ 100 bn; FDA delays fast-track reviews of drugs under Trump’s voucher program
In 2022, Pfizer had crossed US$ 100 billion in revenue owing to its Covid products. While that was a one-off, Johnson & Johnson...
Impressions : 1758
Pfizer, Novo escalate bidding war for obesity-drug developer Metsera; Kimberly-Clark to buy Kenvue for US$ 48.7 bn
As we return from
our one-week break due to the CPhI Worldwide, we find our double-dose Phispers
edition to be filled with se...
Impressions : 1452
Novo targets MASH with up to US$ 5.2bn Akero buy; BMS acquires cell therapy developer Orbital for US$ 1.5 bn
In this week’s Phispers, Novo Nordisk and Bristol Myers Squibb (BMS) struck multi-billion-dollar acquisitions to expand t...
Impressions : 1212
Pfizer buys Metsera for up to US$ 7.3 bn, Roche acquires 89bio; FDA okays injectable version of Merck’s Keytruda
In this week’s Phispers, Pfizer announced the acquisition of New York-based biotech Metsera for up to US$ 7.3 billion, ma...
Impressions : 1806
Novartis inks US$ 5.7 bn licensing deal with Monte Rosa for immune-related diseases; GSK, Lilly pledge more investments in US
In this week’s news, drugmakers continued to invest heavily in the US in order to avoid tariffs. GSK said it will invest ...
Impressions : 1342
White House sacks CDC director; FDA okays Ionis’ Dawnzera, first RNA-based preventive for hereditary angioedema
The Trump administration has fired US Centers for Disease Control and Prevention (CDC) Director Susan Monarez, post a policy di...
Impressions : 1488
FDA grants accelerated nod to Boehringer’s lung cancer med; reinstates ousted CBER chief Vinay Prasad
The US Food and Drug Administration (FDA) has granted an accelerated approval to Boehringer Ingelheim’s Hernexeos (zonger...
Impressions : 1867
Royalty Pharma inks US$ 2 bn cancer drug deal with Revolution; Astra-Daiichi’s Datroway wins US approval for lung cancer
In news this week, Royalty Pharma committed up to US$ 2 billion to Revolution Medicines for their promising pancreatic and lung...
Impressions : 3194
Roche announces US$ 50 bn investment in US to avoid tariffs; Regeneron signs US$ 3 bn onshoring deal with Fujifilm
After Eli Lilly, Johnson & Johnson and Novartis, Roche has announced plans to manufacture in the US to avoid tariffs. The Swiss...
Impressions : 1464
- Privacy policy
- Terms and conditions
- Disclaimers
-
- Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.